1.Eltrombopag Plus Pulsed Dexamethasone As First Line Therapy for Subjects with Immune Thrombocytopenic Purpura (ITP)

Zhang, LQ, Zhang, MJ     More...

Zhang, LQ, Zhang, MJ, Du, X, Cheng, YF, Cheng, G     Less

BLOOD[0006-4971], Published 2018, Volume 132,

收錄情况： WOS

WOS核心合集引用: 1  2022影響因子:  20.3  发表年影響因子:  16.601 

2.Vemurafenib As First Treatment of Hairy Cell Leukemia

Cheng, G, Cheng, G,     More...

Cheng, G, Cheng, G, Chan, NPH, Wong, C, Wong, RS     Less

BLOOD[0006-4971], Published 2014, Volume 124, Issue 21,

收錄情况： WOS

WOS核心合集引用: 0  2022影響因子:  20.3  发表年影響因子:  10.452 

3.Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study

Saleh, MN, Bussel, J     More...

Saleh, MN, Bussel, JB, Cheng, G, Meyer, O, Bailey, CK, Arning, M, Brainsky, A     Less

BLOOD[0006-4971], Published 2013, Volume 121, Issue 3, Pages 537-545

收錄情况： WOS SCOPUS

WOS核心合集引用: 228  2022影響因子:  20.3  发表年影響因子:  9.775 

4.Long-Term Safety and Efficacy of Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP): Report of up to 5.5 Years of Treatment in EXTEND

Saleh, MN, Cheng, G,     More...

Saleh, MN, Cheng, G, Bussel, JB, Burgess, P, Bakshi, K, Brainsky, A, Bailey, CK     Less

BLOOD[0006-4971], Published 2012, Volume 120, Issue 21,

收錄情况： WOS

WOS核心合集引用: 1  2022影響因子:  20.3  发表年影響因子:  9.060 

5.Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

Powell, JS, Josephso     More...

Powell, JS, Josephson, NC, Quon, D, Ragni, MV, Cheng, G, Li, E, Jiang, HY, Li, L, Dumont, JA, Goyal, J, Zhang, X, Sommer, J, McCue, J, Barbetti, M, Luk, A, Pierce, GF     Less

BLOOD[0006-4971], Published 2012, Volume 119, Issue 13, Pages 3031-3037

收錄情况： WOS SCOPUS

WOS核心合集引用: 193  2022影響因子:  20.3  发表年影響因子:  9.060 

6.Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients

Shapiro, AD, Ragni,     More...

Shapiro, AD, Ragni, MV, Valentino, LA, Key, NS, Josephson, NC, Powel, JS, Cheng, G, Thompson, AR, Goyal, J, Tubridy, KL, Peters, RT, Dumont, JA, Euwart, D, Li, L, Hallen, B, Gozzi, P, Bitonti, AJ, Jiang, HY, Luk, A, Pierce, GF     Less

BLOOD[0006-4971], Published 2012, Volume 119, Issue 3, Pages 666-672

收錄情况： WOS SCOPUS

WOS核心合集引用: 139  2022影響因子:  20.3  发表年影響因子:  9.060 

7.Incidence of Thromboembolic Events Across Eltrombopag Clinical Trials In Chronic Immune Thrombocytopenia (ITP)

Bussel, JB, Cheng, G     More...

Bussel, JB, Cheng, G, Saleh, MN, Mayer, B, Vasey, SY, Brainsky, A     Less

BLOOD[0006-4971], Published 2010, Volume 116, Issue 21, Pages 37-38

收錄情况： WOS

WOS核心合集引用: 3  2022影響因子:  20.3  发表年影響因子:  10.558 

8.EXTEND Study Update: Safety and Efficacy of Eltrombopag In Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2010

Saleh, MN, Cheng, G,     More...

Saleh, MN, Cheng, G, Bussel, JB, Sun, HP, Mayer, B, Bailey, C, Brainsky, A     Less

BLOOD[0006-4971], Published 2010, Volume 116, Issue 21, Pages 36-36

收錄情况： WOS

WOS核心合集引用: 3  2022影響因子:  20.3  发表年影響因子:  10.558 

9.Time to Splenectomy Failure in Patients with Recurrent or Refractory Chronic Immune Thrombocytopenic Purpura

Cheng, G, Gernsheime     More...

Cheng, G, Gernsheimer, T, Olney, HJ, Bussel, JB, Shah, P, Brainsky, A, Grotzinger, KM, Aivado, M     Less

BLOOD[0006-4971], Published 2009, Volume 114, Issue 22, Pages 1367-1367

收錄情况： WOS

WOS核心合集引用: 0  2022影響因子:  20.3  发表年影響因子:  10.555 

10.Thromboembolic Events Observed in Eltrombopag Clinical Trials in Chronic Immune Thrombocytopenic Purpura.

Bussel, JB, Cheng, G     More...

Bussel, JB, Cheng, G, Saleh, MN, Vasey, S, Aivado, M, Brainsky, A     Less

BLOOD[0006-4971], Published 2009, Volume 114, Issue 22, Pages 956-957

收錄情况： WOS

WOS核心合集引用: 2  2022影響因子:  20.3  发表年影響因子:  10.555 

11.Long-Term Treatment of Chronic Immune Thrombocytopenic Purpura with Oral Eltrombopag: Results From the EXTEND Study

Saleh, MN, Bussel, J     More...

Saleh, MN, Bussel, JB, Cheng, G, Meddeb, B, Mayer, B, Bailey, C, Aivado, M     Less

BLOOD[0006-4971], Published 2009, Volume 114, Issue 22, Pages 285-286

收錄情况： WOS

WOS核心合集引用: 3  2022影響因子:  20.3  发表年影響因子:  10.555 

12.Evaluation of Hepatobiliary Parameters During Eltrombopag Treatment in Patients with Chronic Immune Thrombocytopenic Purpura

Maddrey, WC, Cheng,     More...

Maddrey, WC, Cheng, G, Khelif, A, Wroblewski, SL, Brainsky, A     Less

BLOOD[0006-4971], Published 2009, Volume 114, Issue 22, Pages 951-952

收錄情况： WOS

WOS核心合集引用: 4  2022影響因子:  20.3  发表年影響因子:  10.555 

13.Platelet Counts Following Eltrombopag Discontinuation in Patients with Chronic Immune Thrombocytopenic Purpura

Cheng, G, Tarantino,     More...

Cheng, G, Tarantino, M, Gernsheimer, T, Meyer, O, Brainsky, A, Stone, NL     Less

BLOOD[0006-4971], Published 2009, Volume 114, Issue 22, Pages 1365-1365

收錄情况： WOS

WOS核心合集引用: 1  2022影響因子:  20.3  发表年影響因子:  10.555 

14.Safety and Efficacy of Long-Term Treatment with Oral Eltrombopag for Chronic Idiopathic Thrombocytopenic Purpura

Bussel, JB, Cheng, G     More...

Bussel, JB, Cheng, G, Saleh, MN, Meddeb, B, Bailey, C, Stone, NL, Aivado, M     Less

BLOOD[0006-4971], Published 2008, Volume 112, Issue 11, Pages 1177-1177

收錄情况： WOS

WOS核心合集引用: 6  2022影響因子:  20.3  发表年影響因子:  10.432 

15.Eltrombopag Delivers Clinical Benefit in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients Not Achieving Platelet Counts >= 50,000/mu L - Data from the EXTEND Study

Cheng, G, Bussel, JB     More...

Cheng, G, Bussel, JB, Saleh, MN, Meddeb, B, De Obaldia, ME, Aivado, M, Stone, NL     Less

BLOOD[0006-4971], Published 2008, Volume 112, Issue 11, Pages 1176-1176

收錄情况： WOS

WOS核心合集引用: 0  2022影響因子:  20.3  发表年影響因子:  10.432 

16.Oral Eltrombopag Treatment Reduces the Need for Concomitant Medications in Patients with Chronic Idiopathic Thrombocytopenic Purpura

Fogarty, PF, Bussel,     More...

Fogarty, PF, Bussel, JB, Cheng, G, Saleh, MN, Meddeb, B, Bailey, C, Brainsky, A     Less

BLOOD[0006-4971], Published 2008, Volume 112, Issue 11, Pages 1174-1174

收錄情况： WOS

WOS核心合集引用: 3  2022影響因子:  20.3  发表年影響因子:  10.432 

17.Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III,. Double-Blind, Placebo-Controlled Study (RAISE)

Cheng, G, Saleh, MN,     More...

Cheng, G, Saleh, MN, Bussel, JB, Marcher, C, Vasey, S, Mayer, B, Aivado, M, Arning, M, Stone, NL     Less

BLOOD[0006-4971], Published 2008, Volume 112, Issue 11, Pages 153-154

收錄情况： WOS

WOS核心合集引用: 4  2022影響因子:  20.3  发表年影響因子:  10.432 

18.Eltrombopag Is Efficacious in Patients with Refractory Chronic Idiopathic Thrombocytopenic Purpura (ITP) - Data from the EXTEND Study

Saleh, MN, Bussel, J     More...

Saleh, MN, Bussel, JB, Cheng, G, Meddeb, B, Burgess, PM, De Obaldia, ME, Stone, NL, Aivado, M     Less

BLOOD[0006-4971], Published 2008, Volume 112, Issue 11, Pages 154-154

收錄情况： WOS

WOS核心合集引用: 0  2022影響因子:  20.3  发表年影響因子:  10.432 

19.Long-term safety and efficacy of oral eltrombopag for-the treatment of subjects with idiopathic thrombocytopenic purpura (ITP): Preliminary data from the EXTEND study

Brussels, JB, Cheng,     More...

Brussels, JB, Cheng, G, Kovaleva, L, Saleh, MN, Meddeb, B, Mayer, B, Fraser, JL, Aivado, M     Less

BLOOD[0006-4971], Published 2007, Volume 110, Issue 11, Pages 174A-174A

收錄情况： WOS

WOS核心合集引用: 0  2022影響因子:  20.3  发表年影響因子:  10.896 

20.Platelet counts remain elevated in two patients with idiopathic thrombocytopenic purpura after cessation of oral eltrombopag

Cheng, G     More...

Cheng, G     Less

BLOOD[0006-4971], Published 2007, Volume 110, Issue 11, Pages 49B-49B

收錄情况： WOS

WOS核心合集引用: 1  2022影響因子:  20.3  发表年影響因子:  10.896